Cagent Vascular completes enrolment of PRELUDE study using Serranator Alto device

By Natalie GoodridgeJune 6, 2017October 29th, 2024Healthcare

No Comments

Cagent Vascular completes enrolment of PRELUDE study using Serranator Alto device

https://vascularnews.com/cagent-vascular-completes-enrolment-of-prelude-study-using-serranator-alto-device/

Tags:

Healthcare Cagent Vascular

PreviousLimFlow Announces First Patient Treated in U.S. Feasibility Study and Commencement of International Post-Market Study
NextLimFlow Expands Senior Management Team and Opens Silicon Valley Office

M&L GROUP

We are a family investment firm that cultivates pioneering ventures into successful enterprises with passion, energy and integrity.

Hospitality

Healthcare

Shipping

Alternatives

Media room

About

Contact

Copyright © 2025 M&L Group. All Rights Reserved. | Legal.

Branding and website design by Stepworks